BiondVax Receives a Confirmation for a Grant of 4.87 million NIS from the Office of the Chief Scientist

The budget is intended for the Continued Clinical Program of the Universal Influenza Vaccine of the Company The Chief Scientist Demonstrates His Continued Confidence, Granting BiondVax NIS 15.7 million Nes Ziona, Israel – 8 September 2014 – BiondVax Pharmaceuticals Ltd. (TASE: BNDX), which is developing the Universal Flu Vaccine, today announced that it has been awarded a sum of 4.87 million NIS by the Chief Scientist in the Ministry of Economy (OCS) for the continued development of BiondVax's Universal Influenza Vaccine in advanced clinical trials. The grant is awarded in accordance with the Israeli law to promote research and development in the industry.The grant approved by OCS will be used to promote the company's effort towards a phase 3 trial with its Universal Vaccine. In addition, the funds will be used for improvements in the manufacturing process and preparation for its scale up, activities which will contribute significantly to its commercialization.Ron Babecoff, BiondVax's CEO's said today: "We are proud for been awarded yet another grant by the OCS. In the last years OCS has expressed its repeated trust in our Universal Vaccine program and we enjoyed considerable financial support that led to our clinical successes. This is another step in our journey to approve the first Universal Flu Vaccine".